Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Influence of steroids on HCV recurrence after liver transplantation: A prospective study.

Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, D'Errico A, Guido M, Merenda R, Neri D, Zanello M, Giannini FM, Grazi GL, Cillo U, Pinna AD.

J Hepatol. 2007 Dec;47(6):793-8. Epub 2007 Sep 24.

PMID:
17928091
2.

A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.

Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A.

Transpl Int. 2005 Dec;18(12):1336-45.

3.

Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.

Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.

J Hepatol. 2006 Apr;44(4):717-22. Epub 2006 Feb 6.

PMID:
16487616
4.

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.

Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J.

Liver Transpl. 2009 Jan;15(1):79-87. doi: 10.1002/lt.21626.

5.

A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.

Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D, Posner MP, Fisher RA.

Liver Transpl. 2007 Jul;13(7):975-83.

6.

Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.

Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.

Transplant Proc. 2009 Apr;41(3):1041-3. doi: 10.1016/j.transproceed.2009.02.030.

PMID:
19376421
7.

[Old donors in liver transplantation for chronic hepatitis C].

Aguilera V, Ponce M, Berenguer M, Moreno R, Rayón JM, Sanjuán F, Prieto M, Mir J.

Rev Esp Enferm Dig. 2007 Oct;99(10):581-7. Spanish.

8.

Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.

Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.

Liver Transpl. 2006 May;12(5):762-7.

9.

Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation.

Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, Furlini G, Bellusci R, Roda E, Cavallari A.

Liver Transpl. 2002 Oct;8(10):884-8.

10.

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.

Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P.

Liver Transpl. 2009 Jan;15(1):37-48. doi: 10.1002/lt.21566.

12.

HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma.

De Martin E, Senzolo M, Boninsegna S, Guido M, Masier A, Germani G, Tomat S, Brolese A, Neri D, Cillo U, Gambato M, Russo FP, Farinati F, Burra P.

Transplant Proc. 2008 Jul-Aug;40(6):1974-5. doi: 10.1016/j.transproceed.2008.05.040.

PMID:
18675104
13.

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation.

Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson RC.

Liver Transpl. 2004 May;10(5):599-606.

14.

Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome.

Carmiel-Haggai M, Fiel MI, Gaddipati HC, Abittan C, Hossain S, Roayaie S, Schwartz ME, Gondolesi G, Emre S, Schiano TD.

Liver Transpl. 2005 Dec;11(12):1567-73.

15.

Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.

Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, Mela M, Manousou P, Senzolo M, Dhillon AP, Patch D, Burroughs AK.

Liver Transpl. 2007 Sep;13(9):1305-11.

16.

The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.

Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G.

Transpl Immunol. 2008 Nov;20(1-2):43-7. doi: 10.1016/j.trim.2008.08.007. Epub 2008 Sep 4.

PMID:
18773958
17.

Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.

Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M.

Liver Transpl. 2009 Jun;15(6):619-28. doi: 10.1002/lt.21761.

18.

Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience.

Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M.

Transplant Proc. 2005 Jul-Aug;37(6):2569-70.

PMID:
16182746
19.

Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.

Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F.

Dig Liver Dis. 2009 May;41(5):350-6. doi: 10.1016/j.dld.2008.09.018. Epub 2008 Nov 28.

PMID:
19046932
20.

Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation.

Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ.

Liver Transpl. 2005 Oct;11(10):1207-13.

Supplemental Content

Support Center